CGEM

Over the past six months, Cullinan Therapeutics' stock has seen a significant increase, gaining 91.2% over the past 12 months and 40.6% year-to-date as of early May 2026. The FDA accepted the NDA for Zipalertinib on April 28, 2026, making Cullinan eligible for up to $130 million in U.S. regulatory milestones and a 50/50 profit share in the U.S. Cullinan Therapeutics provided corporate updates and reported its Fourth Quarter and Full Year 2025 financial results on March 10, 2026, and First Quarter 2026 financial results on May 7, 2026. The company has participated in several investor conferences. Insider selling activity has been reported. Analyst ratings have been largely positive, with a consensus of "Moderate Buy" and an average price target of $30.00.